Sort
85,873 grants matching “alzheimers”
Neuroimaging Analysis Center (NAC)
$2,242,720Ron Kikinis · Brigham And Women'S Hospital · P41 · FY2016 · EB
The impact of music on well-being after diagnosis with Alzheimer's disease or its related dementias
$2,242,475Theresa Anne Allison · Northern California Institute/Res/Edu · RF1 · FY2023 · AG
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targets
$2,242,312Philip L De Jager · Columbia University Health Sciences · U01 · FY2021 · AG
Colorado Adoption/Twin Study of Lifespan behavioral development & cognitive aging (CATSLife2)
$2,241,800Chandra A Reynolds · University Of California Riverside · R01 · FY2021 · AG
Neuroimaging Analysis Center (NAC)
$2,241,498Ron Kikinis · Brigham And Women'S Hospital · P41 · FY2017 · EB
Racial Differences in Late-Life Cognitive decline and risk of Alzheimer's Disease
$2,241,456Lisa L Barnes · Rush University Medical Center · R01 · FY2025 · AG
URBAn Native Elders (URBANE): Risk and Protective Factors for Alzheimer's and Related Dementias
$2,241,118Lonnie A. Nelson · Washington State University · R01 · FY2023 · AG
Ambulatory Methods for Measuring Cognitive Change
$2,240,552Martin J. Sliwinski · Pennsylvania State University, The · U2C · FY2021 · AG
Probing the Role of Chaperone-TPR Complexes in Tau Proteostasis
$2,240,412Jason E Gestwicki · University Of California, San Francisco · RF1 · FY2020 · AG
Urban Air Pollution and Alzheimer's Disease: Risk, Heterogeneity, and Mechanisms
$2,240,263Caleb E Finch · University Of Southern California · P01 · FY2021 · AG
PREVENTABLE Trial Implementation Phase
$2,238,866Karen P Alexander · Duke University · U19 · FY2023 · AG
National Center for Drug Discovery in Neurodegeneration
$2,238,265Ross L Stein · Brigham And Women'S Hospital · U24 · FY2008 · NS
NIA-CMS IAA to Purchase CMS Data for NIA Grantees - Alzheimer's disease
$2,238,116National Institute On Aging · Y01 · FY2024 · AG
Prescribing Cascades among Nursing Home Residents with ADRD
$2,238,104Andrew Reis Zullo · Brown University · RF1 · FY2024 · AG
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial
$2,237,972Michael G Agadjanyan · Institute For Molecular Medicine · U01 · FY2022 · AG
A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial
$2,237,103Mark Gregory Luciano · Johns Hopkins University · U01 · FY2025 · NS
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease
$2,236,723Gino A Cortopassi · University Of California At Davis · P01 · FY2020 · AG
Neurological and digital correlates of cognition in Older Mandarin-speaking Adults
$2,236,070William Tzu-Lung Hu · Rutgers Biomedical And Health Sciences · RF1 · FY2023 · AG
The regulation of synaptic transmission and neural circuit function
$2,235,917Wei Lu · National Institute Of Neurological Disorders And Stroke · ZIA · FY2023 · NS
Project 2: Aging Healthy Together: Precision Profiles of Resilience and Risk
$2,235,915Lee Ryan · University Of Arizona · U19 · FY2023 · AG
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease
$2,235,177Gino A Cortopassi · University Of California At Davis · P01 · FY2022 · AG
Prenatal and Early Life Antecedents of Personality: An Intergenerational Lifespan Approach
$2,235,167Angelina R Sutin · Florida State University · RF1 · FY2023 · AG
Center for Targeted Therapeutics
$2,235,000Hippokratis Kiaris · University Of South Carolina At Columbia · P20 · FY2023 · GM
Center for Targeted Therapeutics
$2,235,000Igor B Roninson · University Of South Carolina At Columbia · P20 · FY2019 · GM
Center for Targeted Therapeutics
$2,235,000Igor B Roninson · University Of South Carolina At Columbia · P20 · FY2020 · GM